NATCO receives establishment inspection report for Kothur facility

Published: 05.08.2019 21:50
NATCO receives establishment inspection report for Kothur facility
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted at its drug formulations facility in Kothur Village, Telangana, India, during the period May 30th – June 5th, 2019.

 


Copyright © 2007-2018 by PSS Pharmaceuticals International All Rights Reserved.